The impending loss of exclusivity for Eliquis (apixaban) is poised to become one of the most significant revenue-generating events in…
Read More
BioNTech Pivots Dramatically to Oncology Amidst Waning Vaccine Revenue and Federal Shift, Cutting 1,860 Jobs and Investing €16.8 Billion in Cash
The German biotechnology powerhouse BioNTech, once synonymous with its groundbreaking COVID-19 vaccine, Comirnaty, is undergoing a profound strategic transformation, shedding…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
The Ascent to Pharmaceutical Leadership Eli Lilly’s journey to the top has been nothing short of meteoric. In 2020, the…
Read More
Eli Lilly Ascends to Pharmaceutical Revenue Pinnacle Amidst Oral GLP-1 Approval, Yet Wall Street Remains Measured
Indianapolis-based pharmaceutical giant Eli Lilly and Company has achieved a remarkable milestone, surpassing all global pharmaceutical competitors to claim the…
Read More
Lilly Emerges as Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s $36.5 Billion Success
Eli Lilly and Company has officially concluded its fiscal year 2025 as the world’s leading pharmaceutical enterprise by revenue, a…
Read More
Eli Lilly Ascends to Pharma’s Top Revenue Spot Amidst Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced.
Eli Lilly and Company, a venerable titan in the pharmaceutical industry, has achieved an unprecedented milestone, claiming the top spot…
Read More
Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth
Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…
Read More
Eli Lilly is now pharma’s top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn’t celebrating
In a landmark announcement on April 1, the U.S. Food and Drug Administration (FDA) granted approval to Foundayo (orforglipron), Eli…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has achieved a historic milestone, concluding fiscal year 2025 as the world’s highest-earning pharmaceutical company by…
Read More
Lilly Ascends to Pharma’s Top Revenue Spot Amidst Landmark Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced
Eli Lilly and Company has officially claimed the top spot among global pharmaceutical companies by revenue, a monumental achievement underscored…
Read More
